AJP - Renal Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

Am J Physiol Renal Physiol (December 16, 2003). doi:10.1152/ajprenal.00163.2003
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
286/4/F653    most recent
00163.2003v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Banes, A. K.
Right arrow Articles by Marrero, M. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Banes, A. K.
Right arrow Articles by Marrero, M. B.
Submitted on April 24, 2003
Accepted on December 11, 2003

Angiotensin II blockade prevents hyperglycemia-induced activation of JAK and STAT proteins in diabetic rat kidney glomeruli

Amy K. Banes1, Sean Shaw1, John A. Jenkins1, Heather Redd1, Farhad Amiri1, David M. Pollock1, and Mario B. Marrero1*

1 Vascular Biology Center, Medical College of Georgia, Augusta, Georgia, USA

* To whom correspondence should be addressed. E-mail: mmarrero{at}mail.mcg.edu.

Clinical and animal studies show that treatment with angiotensin-converting enzyme (ACE) inhibitors or angiotensin II (Ang II) receptor antagonists slows progression of nephropathy in diabetes, indicating Ang II plays an important role in its development. We previously reported that hyperglycemia augments both Ang II-induced growth and activation of JAK2 and STAT proteins in cultured rat mesangial cells. Furthermore, we demonstrated that the tyrosine kinase enzyme JAK2 plays a key role in both Ang II- and hyperglycemia-induced growth in these cells. We hypothesized that the ACE inhibitor, captopril, and the Ang II receptor antagonist candesartan would hinder hyperglycemic-induced activation of JAK and STAT proteins in rat glomeruli, demonstrating that Ang II plays an important role in the activation of these proteins in vivo. Adult male Sprague-Dawley rats were given either streptozotocin (STZ; 60 mg/Kg) or vehicle, i.v., and glomeruli were isolated 2 wk later. Activation of JAK and STAT proteins was evaluated by Western blot analysis for specific tyrosine phosphorylation. Groups of rats were given: captopril (75-85 mg/Kg/day), candesartan (10 mg/Kg/day) or the JAK2 inhibitor AG490 (5 mg/Kg/day)for the study's duration. STZ stimulated glomerular phosphorylation of JAK2, STAT1, STAT3 and STAT5. Phosphorylation was reduced in rats treated with captopril, candesartan and AG490. Furthermore, both candesartan and AG490 inhibited STZ-induced increases in urinary protein excretion. In conclusion, our studies demonstrate that hyperglycemia induces activation of JAK2 and the STATs in vivo via an Ang II dependent mechanism and that these proteins may be involved in the early kidney damage associated with diabetes.




This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
T. Arakawa, T. Masaki, T. Hirai, S. Doi, M. Kuratsune, K. Arihiro, N. Kohno, and N. Yorioka
Activation of signal transducer and activator of transcription 3 correlates with cell proliferation and renal injury in human glomerulonephritis
Nephrol. Dial. Transplant., November 1, 2008; 23(11): 3418 - 3426.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
Y. Qian, E. Feldman, S. Pennathur, M. Kretzler, and F. C. Brosius III
From Fibrosis to Sclerosis: Mechanisms of Glomerulosclerosis in Diabetic Nephropathy
Diabetes, June 1, 2008; 57(6): 1439 - 1445.
[Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
N. Yang, M. Luo, R. Li, Y. Huang, R. Zhang, Q. Wu, F. Wang, Y. Li, and X. Yu
Blockage of JAK/STAT signalling attenuates renal ischaemia-reperfusion injury in rats
Nephrol. Dial. Transplant., January 1, 2008; 23(1): 91 - 100.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
A. K. L. Banes-Berceli, P. Ketsawatsomkron, S. Ogbi, B. Patel, D. M. Pollock, and M. B. Marrero
Angiotensin II and endothelin-1 augment the vascular complications of diabetes via JAK2 activation
Am J Physiol Heart Circ Physiol, August 1, 2007; 293(2): H1291 - H1299.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
A. K. Banes-Berceli, S. Shaw, G. Ma, M. Brands, D. C. Eaton, D. M. Stern, D. Fulton, R. W. Caldwell, and M. B. Marrero
Effect of simvastatin on high glucose- and angiotensin II-induced activation of the JAK/STAT pathway in mesangial cells
Am J Physiol Renal Physiol, July 1, 2006; 291(1): F116 - F121.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
M. B. Marrero, A. K. Banes-Berceli, D. M. Stern, and D. C. Eaton
Role of the JAK/STAT signaling pathway in diabetic nephropathy
Am J Physiol Renal Physiol, April 1, 2006; 290(4): F762 - F768.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Cell Physiol.Home page
A. K. L. Banes, S. M. Shaw, A. Tawfik, B. P. Patel, S. Ogbi, D. Fulton, and M. B. Marrero
Activation of the JAK/STAT pathway in vascular smooth muscle by serotonin
Am J Physiol Cell Physiol, April 1, 2005; 288(4): C805 - C812.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Visit Other APS Journals Online
Copyright © 1976 by the American Physiological Society.